Cargando…
An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
Breast cancer patients undergoing neoadjuvant chemotherapy (NAC) require precise and accurate evaluation of treatment response. Residual cancer burden (RCB) is a prognostic tool widely used to estimate survival outcomes in breast cancer. In this study, we introduced a machine-learning-based optical...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303311/ https://www.ncbi.nlm.nih.gov/pubmed/37420927 http://dx.doi.org/10.3390/s23125761 |
_version_ | 1785065248200327168 |
---|---|
author | Momtahen, Shadi Momtahen, Maryam Ramaseshan, Ramani Golnaraghi, Farid |
author_facet | Momtahen, Shadi Momtahen, Maryam Ramaseshan, Ramani Golnaraghi, Farid |
author_sort | Momtahen, Shadi |
collection | PubMed |
description | Breast cancer patients undergoing neoadjuvant chemotherapy (NAC) require precise and accurate evaluation of treatment response. Residual cancer burden (RCB) is a prognostic tool widely used to estimate survival outcomes in breast cancer. In this study, we introduced a machine-learning-based optical biosensor called the Opti-scan probe to assess residual cancer burden in breast cancer patients undergoing NAC. The Opti-scan probe data were acquired from 15 patients (mean age: 61.8 years) before and after each cycle of NAC. Using regression analysis with k-fold cross-validation, we calculated the optical properties of healthy and unhealthy breast tissues. The ML predictive model was trained on the optical parameter values and breast cancer imaging features obtained from the Opti-scan probe data to calculate RCB values. The results show that the ML model achieved a high accuracy of 0.98 in predicting RCB number/class based on the changes in optical properties measured by the Opti-scan probe. These findings suggest that our ML-based Opti-scan probe has considerable potential as a valuable tool for the assessment of breast cancer response after NAC and to guide treatment decisions. Therefore, it could be a promising, non-invasive, and accurate method for monitoring breast cancer patient’s response to NAC. |
format | Online Article Text |
id | pubmed-10303311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103033112023-06-29 An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Momtahen, Shadi Momtahen, Maryam Ramaseshan, Ramani Golnaraghi, Farid Sensors (Basel) Article Breast cancer patients undergoing neoadjuvant chemotherapy (NAC) require precise and accurate evaluation of treatment response. Residual cancer burden (RCB) is a prognostic tool widely used to estimate survival outcomes in breast cancer. In this study, we introduced a machine-learning-based optical biosensor called the Opti-scan probe to assess residual cancer burden in breast cancer patients undergoing NAC. The Opti-scan probe data were acquired from 15 patients (mean age: 61.8 years) before and after each cycle of NAC. Using regression analysis with k-fold cross-validation, we calculated the optical properties of healthy and unhealthy breast tissues. The ML predictive model was trained on the optical parameter values and breast cancer imaging features obtained from the Opti-scan probe data to calculate RCB values. The results show that the ML model achieved a high accuracy of 0.98 in predicting RCB number/class based on the changes in optical properties measured by the Opti-scan probe. These findings suggest that our ML-based Opti-scan probe has considerable potential as a valuable tool for the assessment of breast cancer response after NAC and to guide treatment decisions. Therefore, it could be a promising, non-invasive, and accurate method for monitoring breast cancer patient’s response to NAC. MDPI 2023-06-20 /pmc/articles/PMC10303311/ /pubmed/37420927 http://dx.doi.org/10.3390/s23125761 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Momtahen, Shadi Momtahen, Maryam Ramaseshan, Ramani Golnaraghi, Farid An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title | An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_full | An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_fullStr | An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_full_unstemmed | An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_short | An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy |
title_sort | optical sensory system for assessment of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303311/ https://www.ncbi.nlm.nih.gov/pubmed/37420927 http://dx.doi.org/10.3390/s23125761 |
work_keys_str_mv | AT momtahenshadi anopticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy AT momtahenmaryam anopticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy AT ramaseshanramani anopticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy AT golnaraghifarid anopticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy AT momtahenshadi opticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy AT momtahenmaryam opticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy AT ramaseshanramani opticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy AT golnaraghifarid opticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy |